Sami Alom

Prior to joining Kasamar, Sami was the Chief Strategy Officer and Director of Investor Relations of the Al Noor Hospitals Group from January 2011 to March 2016.
His primary responsibilities included corporate strategy, business development, and M&A.
He carried out four acquisitions including that of the Gulf International Cancer Center.
Additionally, Sami was one of two executives in Al Noor that played a key role in the company's IPO (USD 1.0Bn valuation) in June 2013 and one of three that played a key role in its reverse merger with Mediclinic International (USD 10Bn valuation) in February 2016.
In addition to his role at Kasamar, Sami has served since 2012 as Adjunct Assistant Professor at the College of Medicine and Health Sciences, UAE University.
He previously served as a member of the Health Sector committee of the Abu Dhabi Chamber of Commerce.
Prior to Al Noor, Sami worked at The Johns Hopkins Hospital Department of Perioperative Services and Department of Anaesthesia and Critical Care Medicine as a Senior Data Analyst, and prior to that he was a post-doctoral fellow at the Tissue Microfabrication Lab at the University of Pennsylvania.
Sami received his PhD in Biomedical Engineering from The Johns Hopkins University School of Medicine where his thesis focused on researching stem cells.
He also holds a MPH, MBA, and a BS in Biomedical Engineering from Johns Hopkins.